1. Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. (1st November 2019) Authors: Mirza, MR; Dørum, A; Benigno, B; Mahner, S; Bessette, P; Bover Barcelo, IM; Berton, D; Ledermann, J; Rimel, BJ; Herrstedt, J; Lau, S; Canzler, U; Palacio Vázquez, I; Kalbacher, E; Buscema, J; Lorusso, D; Debruyne, P; Bruchim, I; Guo, W; Gupta, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. (18th December 2017) Authors: Friedlander, M; Rau, J; Lee, C K; Meier, W; Lesoin, A; Kim, J -W; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, M T; Debruyne, P; Bologna, A; Malander, S; Monk, B J; Petru, E; Calvert, P; Herzog, T J; Barrett, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗